Narayana Hrudayalaya Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,844 Cr +73% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
NH

Narayana Hrudayalaya Ltd

Q3 FY26Healthcare Services

Narayana Hrudayalaya Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,151Cr
+61.1% YoY
+30.8% QoQ
Net profit
₹127Cr
−34.2% YoY
−50.8% QoQ
Margin
17%
−6 pp YoY
−7 pp QoQ
Price₹1,816
Market cap₹38.9K Cr
P/E45.1

The short version

India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12). India business is expected to sustain double-digit revenue growth with continued margin expansion driven by transformation programs and payor mix optimization initiatives.

From Narayana Hrudayalaya Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12).
  • Oncology and cardiac: Projected to account for more than half of revenue going forward, with oncology potentially increasing by 20% (Page 9).
  • Expansion focus: Consolidating core markets like Bangalore and Kolkata, with investments in new flagship facilities (Page 14).
  • UK operations: Growth expected through improving performance and expanding private market share, though margins will differ from other markets (Page 15).
  • Cayman operations: Expected to sustain revenue levels (Page 14).

2 more points from Narayana Hrudayalaya Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Narayana Hrudayalaya Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • India CapEx: Planned INR 1000 crore (internal accruals and debt funding); actual closer to INR 3000 crore for expansion, mainly in Bangalore, Kolkata, and Raipur clusters (Page 12, 14, 25).
  • Addition of four DaVinci robotic surgery systems across hospitals in India next year for advanced surgical capabilities (Page 23).
  • Minor equipment and sterilization units CapEx in Birmingham (UK) has mostly been completed; no major remaining CapEx (Page 17).
  • Investment in oncology joint ventures in India: Everhope Oncology (chemo centers in Delhi/Gurgaon) and SSO Oncology in Mumbai with plans to expand; no earmarked further investments yet pending business trajectory (Page 25).

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Narayana Hrudayalaya Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Narayana Hrudayalaya Ltd said on order book & pipeline — free account, 30 seconds.

Narayana Hrudayalaya Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Narayana Hrudayalaya Ltd Q3 FY26 results — key figures

Narayana Hrudayalaya Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue2,1511,335+61.1%1,644+30.8%
Operating profit (EBITDA)365307+18.9%401-9%
Operating margin17%23%-6 pp24%-7 pp
Profit before tax149219-32%296-49.7%
Net profit (PAT)127193-34.2%258-50.8%
EPS (₹)6.209.44-34.3%12.64-50.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹301 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q3 FY26)

    FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —

  • Aster DM Quality (Q3 FY26)

    Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…

  • Chandan Healthca (Q3 FY26)

    The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…

  • Rainbow Childrens Medicare (Q3 FY26)

    Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Narayana Hrudayalaya Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Narayana Hrudayalaya Ltd Q3 FY26 results?

India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12). India business is expected to sustain double-digit revenue growth with continued margin expansion driven by transformation programs and payor mix optimization initiatives.

What is Narayana Hrudayalaya Ltd share price analysis?

Narayana Hrudayalaya Ltd currently shows a neutral. The stock trades at a P/E of 45.1 with a market cap of ₹38,892 Cr. Investors should review the full earnings analysis for detailed insights.

Is Narayana Hrudayalaya Ltd planning capital expenditure?

India CapEx: Planned INR 1000 crore (internal accruals and debt funding); actual closer to INR 3000 crore for expansion, mainly in Bangalore, Kolkata, and Raipur clusters (Page 12, 14, 25).

Keep Narayana Hrudayalaya Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.